

OMICS and AI in PROSTATE CANCER

Omics driven systemic treatments

Roberto lacovelli MD PhD



Università Cattolica del Sacro Cuore



Comprehensive Cancer Center









roberto.iacovelli@policlinicogemelli.it



Disclosures:

Type of conflict	Sponsor
Participation at advisory board	Astellas, BMS, Ipsen, Janssen, Merk, MSD, Pfizer, Sanofi, Bayer, EISAI.
Consultancy	Astellas, Ipsen, Merk, MSD, Pfizer, EISAI.
Research support (inst)	BMS, Pfizer.
I am a clinician	Myself





Genomics as a way for personalized medicine (also in Pca):



				1-800-4-	CANCER	Live Chat	Publications	Dictionary			
BOUT CANCER	CANCER TYPES	RESEARCH	GRANTS & TRAINING	NEWS & EVENTS	ABOUT N	ICI search	ı	Q			
me > Publications > I	NCI Dictionaries										
UBLICATIONS			lized medicin	e							
atient Education ublications		(PER-suh-nuh-LIZED MEH-dih-sin) A form of medicine that uses information about a person's own genes or proteins to prevent, diagnose, or treat									
DQ®	+	disease. In cancer, personalized medicine uses specific information about a person's tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis. Examples of personalized medicine include using targeted therapies to treat specific types of cancer cells, such as HER2-positive breast cancer cells, or using tumor marker testing to help diagnose cancer. Also called precision medicine.									
act Sheets											
CI Dictionaries											
Dictionary of Cance Terms	·	medicine.									
Drug Dictionary		More Inform	ation								
Dictionary of Geneti Terms	cs	Biomarker Test	ng for Cancer Treatment	t							





Español

The clinical point of view when using genomics/genetics:


- How genomic/genetic knowledges have impacted PCa treatment?
- How deeper genomic/genetic knowledges can affect PCa treatment?
- Considerations about the potential of genomics and the role of ctDNA in clinical management of PCa.



How genomic/genetic knowledges have impacted PCa treatment?


TOPARP-A study


A Radiologic Progression-free Survival





MODERN RADIATION ONCOLOGY





49 heavily pretreated mCRPC men treated with PARP inhibitor (olaparib 400 mg BID)


Genomic signature of PARP inhibitor sensitivity in 16/49 (33%)

Response to PARP in 14/16 (87,5%)

Mateo J et al. New Engl J Med. 2015;373:1697-708

How genomic/genetic knowledges have impacted PCa treatment?

A Imaging-Based Progression-free Survival in Cohort A




*An investigational Clinical Trial Assay, based on the FoundationOne® CDx next-generation sequencing test

Developed in partnership with Foundation Medicine Inc, and used to prospectively select patients harboring alterations in BRCA1, BRCA2, ATM,

Igress ‡Physician's choice of either enzalutamide (160 mg qd) or abiraterone (1000 mg qd + prednisone [5 mg bid])

BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D and/ or RAD54L in their tumor tissue



Median mo Olaparib 7.4 Control 3.6 Hazard ratio for progression or death, 0.34 (95% CI, 0.25-0.47) P<0.001</td> P


0

Months since Randomization

No. at Risk

 Olaparib
 162
 149
 126
 116
 102
 101
 82
 77
 56
 53
 42
 37
 26
 24
 18
 11
 11
 3
 2
 0
 0
 0

 Control
 83
 79
 47
 44
 22
 20
 13
 12
 7
 6
 3
 3
 2
 2
 1
 1
 1
 0
 0
 0



De Bono J, et al. N Engl J Med 2020; 382:2091-2102

BICR. blinded independent central review


 Olaparib
 162
 158
 155
 150
 147
 141
 136
 125
 115
 95
 86
 76
 67
 59
 50
 46
 33
 26
 17
 11
 4
 3
 2
 0

 Control
 83
 82
 79
 76
 74
 72
 69
 69
 54
 50
 44
 40
 34
 29
 25
 23
 18
 15
 11
 9
 6
 3
 1
 1
 0




Measurable disease

PROpel: global randomized double-blind Phase III trial¹








Saad F, ESMO 2022; Presentation number: 13570



Patients enrolled in TOPARP-B study and analyzed based on the type of mutation:




"BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA2 deletion".

Carreira S, et al. Cancer Discov. 2021;11:2812-2827.



De-identified tumor and blood massively parallel sequencing data of 21.333 cancer patients enrolled in the study




Sixteen genes were included in these analyses, including seven HR deficiency (HRD) genes (BRCA2, BRCA1, PALB2, BRIP1, RAD51D, RAD51C and BAP1), two DDR genes (ATM and CHEK2), four MMR genes (MSH2, PMS2, MLH1 and MSH6) as well as NF1, RB1 and TP53.



HRR mutations might select patients more responsive to some therapies...

Patients with gHR alterations may benefit from Radium-223 more than non-carriers



Presented by Dr Castro at ESMO 2021




Elena Castro MD PhD

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.



...but not to all!




- Mutations of BRCA1/2 and ATM genes did not predict a better response to taxane-based chemo.
- These alteration remain prognostics.

Mateo J, et al. Eur Urol. 2018;73(5):687-693. Castro E, et al. J Clin Oncol. 2019;37:490-503.




Considerations about the potential of genomics and the role of test in PCa.





Considerations about the potential of genomics and the role of test in PCa.

Figure 1. Genomic landscape of GAs detected in advanced prostate cancer liquid biopsies



The genomic landscape of prostate cancer ctDNA largely recapitulates that detected by tissue biopsies.


BRCA1/2 alterations: 8.8% AR alterations: 42% PI3K/AKT/mTOR: 14% WNT/β-catenin: 17% RAS/RAF/MEK: 5%

Note: homozygous deletions not reported by the assays in this study (affecting *PTEN*, *RB1*, *BRCA1/2*). *TMPRSS2-ERG* and *SPOP* were not baited.

ODERN RADIATION ONCOLOGY

Considerations about the potential of genomics and the role of test in PCa.





(A) Contingency table showing detection of BRCA1/2 short variants and rearrangements by liquid and tissue biopsy. (B) ctDNA fractions and variant allele frequencies (VAF) of BRCA1/2 variants detected in 92 tissue/liquid pairs. PPA: positive percent agreement; NPA: negative percent agreement; OPA: overall percent agreement. Short variant: substitution, short insertion/deletion.

There was a high level of agreement in detection of *BRCA1/2* alterations between tissue and liquid biopsy. Patients with tissue-only detection of *BRCA1/2* had liquid biopsies with low ctDNA fraction.

PRESENTED AT: Genitourinary Cancers Symposium

y of the author, perm IDOSIUM required for reuse

Slides are the property of the author, permission required for reuse.



Conclusions

